ZymoGenetics starts study, receiving $70 million
ZymoGenetics starts study on potential hepatitis C drug, receives $70 million from partner
* On 6:26 am EDT, Tuesday October 27, 2009
SEATTLE (AP) -- ZymoGenetics Inc. said Tuesday it started a midstage study on a potential hepatitis C treatment, triggering a $70 million payment from its partner, Bristol-Myers Squibb Co.
The Seattle company is studying PEG-Interferon lambda called IL-29, as a potential combination treatment the hepatitis C drug ribavirin. It could receive up to $1.12 billion in the collaboration with Bristol-Myers.
Shares of ZymoGenetics closed at $5.40 Monday, while shares of Bristol-Myers, which is headquartered in New York, closed at $21.92.
Copyright © 2009 The Associated Press. All rights reserved. The information contained in the AP News report may not be published, broadcast, rewritten, or redistributed without the prior written authority of The Associated Press.
Market Data 
Markets 
AI
